Matthew Biegler
Stock Analyst at Oppenheimer
(3.33)
# 949
Out of 5,152 analysts
91
Total ratings
39.02%
Success rate
6.99%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Biegler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TYRA Tyra Biosciences | Maintains: Outperform | $36 → $50 | $34.54 | +44.76% | 7 | Feb 3, 2026 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Outperform | $750 → $865 | $764.93 | +13.08% | 1 | Feb 2, 2026 | |
| RLAY Relay Therapeutics | Upgrades: Outperform | $14 | $9.64 | +45.23% | 7 | Jan 26, 2026 | |
| OLMA Olema Pharmaceuticals | Maintains: Outperform | $45 → $48 | $22.56 | +112.77% | 10 | Dec 11, 2025 | |
| AAPG Ascentage Pharma Group International | Initiates: Outperform | $45 | $22.20 | +102.70% | 1 | Dec 4, 2025 | |
| ORIC ORIC Pharmaceuticals | Maintains: Outperform | $12 → $15 | $13.85 | +8.30% | 6 | Nov 14, 2025 | |
| BBOT BridgeBio Oncology Therapeutics | Maintains: Outperform | $23 → $22 | $9.97 | +120.66% | 2 | Nov 13, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Outperform | $30 → $28 | $15.22 | +83.97% | 3 | Oct 10, 2025 | |
| ACRV Acrivon Therapeutics | Maintains: Outperform | $9 → $8 | $1.60 | +400.00% | 4 | Aug 14, 2025 | |
| CTMX CytomX Therapeutics | Initiates: Outperform | $7 | $4.77 | +46.75% | 1 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $9 | $2.31 | +289.61% | 2 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $160 | $14.56 | +998.90% | 7 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $13.72 | +227.99% | 5 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $105 → $115 | $145.14 | -20.77% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $53 | $33.03 | +60.46% | 5 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $2.19 | +815.33% | 7 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $6.88 | - | 4 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $8.16 | +71.57% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $11.82 | - | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.38 | - | 5 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $12.78 | - | 2 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.46 | - | 3 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $1.20 | - | 2 | Dec 22, 2022 |
Tyra Biosciences
Feb 3, 2026
Maintains: Outperform
Price Target: $36 → $50
Current: $34.54
Upside: +44.76%
Regeneron Pharmaceuticals
Feb 2, 2026
Reiterates: Outperform
Price Target: $750 → $865
Current: $764.93
Upside: +13.08%
Relay Therapeutics
Jan 26, 2026
Upgrades: Outperform
Price Target: $14
Current: $9.64
Upside: +45.23%
Olema Pharmaceuticals
Dec 11, 2025
Maintains: Outperform
Price Target: $45 → $48
Current: $22.56
Upside: +112.77%
Ascentage Pharma Group International
Dec 4, 2025
Initiates: Outperform
Price Target: $45
Current: $22.20
Upside: +102.70%
ORIC Pharmaceuticals
Nov 14, 2025
Maintains: Outperform
Price Target: $12 → $15
Current: $13.85
Upside: +8.30%
BridgeBio Oncology Therapeutics
Nov 13, 2025
Maintains: Outperform
Price Target: $23 → $22
Current: $9.97
Upside: +120.66%
Nurix Therapeutics
Oct 10, 2025
Maintains: Outperform
Price Target: $30 → $28
Current: $15.22
Upside: +83.97%
Acrivon Therapeutics
Aug 14, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $1.60
Upside: +400.00%
CytomX Therapeutics
Jul 31, 2025
Initiates: Outperform
Price Target: $7
Current: $4.77
Upside: +46.75%
May 14, 2025
Maintains: Outperform
Price Target: $10 → $9
Current: $2.31
Upside: +289.61%
Mar 21, 2025
Reiterates: Outperform
Price Target: $160
Current: $14.56
Upside: +998.90%
Feb 12, 2025
Maintains: Outperform
Price Target: $40 → $45
Current: $13.72
Upside: +227.99%
Dec 10, 2024
Reiterates: Outperform
Price Target: $105 → $115
Current: $145.14
Upside: -20.77%
Oct 29, 2024
Reiterates: Outperform
Price Target: $53
Current: $33.03
Upside: +60.46%
Sep 16, 2024
Reiterates: Outperform
Price Target: $20
Current: $2.19
Upside: +815.33%
Jul 2, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $6.88
Upside: -
May 14, 2024
Maintains: Outperform
Price Target: $16 → $14
Current: $8.16
Upside: +71.57%
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $11.82
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.38
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $12.78
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $2.46
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $1.20
Upside: -